Clinical Trial: NCT03789110
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Dana-Farber Cancer Institute |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-04-28 |
Study Overview
Brief Summary
This research study is studying a drug combination of nivolumab and ipilimumab as a possible treatment for hypermutated HER2 negative breast cancer.
The drugs involved in this study are:
- Nivolumab (Opdivo ®)
- Ipilimumab (Yervoy ®)
Official Title
NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Conditions
Breast Cancer
Intervention / Treatment
- Drug: Nivolumab
- Drug: Ipilimumab
Other Study ID Numbers
- 18-561
Start Date (Actual)
2019-03-08
Primary Completion Date (Actual)
2021-09-30
Study Completion Date (Estimated)
2027-02-28
Enrollment (Actual)
30
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Dana-Farber Cancer Institute |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-04-28 |
Study Overview
Brief Summary
This research study is studying a drug combination of nivolumab and ipilimumab as a possible treatment for hypermutated HER2 negative breast cancer.
The drugs involved in this study are:
- Nivolumab (Opdivo ®)
- Ipilimumab (Yervoy ®)
Official Title
NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Conditions
Breast Cancer
Intervention / Treatment
- Drug: Nivolumab
- Drug: Ipilimumab
Other Study ID Numbers
- 18-561
Start Date (Actual)
2019-03-08
Primary Completion Date (Actual)
2021-09-30
Study Completion Date (Estimated)
2027-02-28
Enrollment (Actual)
30
Study Type
Interventional
Phase
Phase 2